Treatment of idiopathic light chain deposition disease: complete remission with
            bortezomib and dexamethasone

Filho, João Tadeu Damian Souto; Monteiro, Jorge Murilo Grillo; Andrade, Inez Barcellos de

doi:10.5935/0101-2800.20160071

Search citation statements

Order By: Relevance

Paper Sections

Select...

Current Treatments and Outlook For Novel Therapies1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2017

2019

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 11 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A case report was published of a patient with LCDD who responded to MEVP (melphalan + cyclophosphamide + vincristine + prednisolone) chemotherapy, with no nodular glomerular lesions 7 years after MEVP treatment [44]. A complete haematological response, marked with a reduction in proteinuria, and improved renal function were observed in another patient with idiopathic LCDD that was treated with vincristine + dexamethasone (VD) [45].…”

Section: Current Treatments and Outlook For Novel Therapiesmentioning

confidence: 99%

The pathogenesis of renal injury and treatment in light chain deposition disease

Wang¹,

Jiang²,

Xu³

2019

J Transl Med

View full text Add to dashboard Cite

Light chain deposition disease (LCDD) is a rare clinical disorder. The deposition of light chain immunoglobulins mainly affects the kidneys, which have different characteristics than other tissues. To date, the therapeutic approach for the treatment of LCDD has no evidence-based consensus, and clinical experience of reported cases guides current disease management strategies. The present systematic review investigates and summarizes the pathological mechanisms of renal injury and the subsequent treatments for LCDD.

show abstract

Section: Current Treatments and Outlook For Novel Therapiesmentioning

confidence: 99%